Riociguat

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

CAS number: 625115-55-1; Methyl-N-[4,6-Diamino-2-[1-[(2-fluorphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminat

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Drug that can be used to treat chronic thromboembolic pulmonary hypertension (CTEPH) and special forms of pulmonary arterial hypertension (PAH). Encouraging results have been obtained in systemic scleroderma. Riociguat acts as a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide signaling pathway.

Note(s)This section has been translated automatically.

Nitric oxide (NO) acts as a signal molecule in smooth muscle cells, for the dilation of blood vessels.

In patients with pulmonary arterial hypertension (PAH), the enzyme NO synthase, which is responsible for NO production, is only present in reduced amounts. As a result, these patients have lower concentrations of cell-produced NO and vasoconstriction. NO binds as a signal molecule to the enzyme soluble guanylate cyclase (sGC) and thus induces the production of the secondary signal molecule (second messenger) cyclic guanosine monophosphate (cGMP).

Riociguat acts as a direct stimulator of guanylate cyclase independent of NO. Furthermore, riociguat acts synergistically to NO and achieves anti-aggregatory, anti-proliferative and vasodilatory effects.

LiteratureThis section has been translated automatically.

  1. Distler O et al (2017) RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respir Med 122 Suppl 1:S14-S17.

Authors

Last updated on: 29.10.2020